Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
---|---|---|---|---|---|---|
|
glucose tolerance
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Postprandial glucose. Invervention vs. controls. | UM-HET3 population | both | various | 2004-2024 |